# Celcuity (CELC) — Overview

CELC · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/celc

## Price

Last close $60.30 on Oct 15, 2026. 52-week range $46.20 – $144.98.

## Company profile

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

## Financials

| Metric | Value |
| --- | --- |
| Revenue (trailing twelve months) | $0.00 |
| Revenue (quarter) | $0.00 |
| Revenue growth (year over year) | 0.00% |
| Gross profit (trailing twelve months) | $0.00 |
| Gross margin | 0.00% |
| Net income (trailing twelve months) | $0.00 |
| Net income (quarter) | −$78.9M |
| Net income growth (year over year) | -74.22% |
| Net margin | 0.00% |
| Return on equity | -1433.70% |
| EPS (trailing twelve months) | −$4.30 |
| Book value per share | −$0.26 |
| P/E (trailing twelve months) | — |
| Price to book | — |
| Debt to assets | 101.54% |
| Payout ratio | 0.00% |
| Dividend yield | 0.00% |

## Frequently Asked Questions

### How do I buy stock in Celcuity (CELC)?

CELC trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at [Light Horse Dashboard](https://portal.lighthorse.io), the trading API, or an [AI agent connected over MCP](/instructions/ai/claude). The trade panel on this page places the order once you are signed in.

---

Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).